Terms: = Lymphoma AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL
22826 results:
1. Hyper-N-glycosylated SEL1L3 as auto-antigenic B-cell receptor target of primary vitreoretinal lymphomas.
Elbert M; Neumann F; Kiefer M; Christofyllakis K; Balensiefer B; Kos I; Carbon G; Kaddu-Mulindwa D; Bittenbring JT; Fadle N; Regitz E; Fend F; Bonzheim I; Thurner L; Bewarder M
Sci Rep; 2024 Apr; 14(1):9571. PubMed ID: 38671086
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France.
Alcazer V; Le Meur G; Roccon M; Barriere S; Le Calvez B; Badaoui B; Spaeth A; Kosmider O; Freynet N; Eveillard M; Croizier C; Chevalier S; Sujobert P
Lancet Digit Health; 2024 May; 6(5):e323-e333. PubMed ID: 38670741
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract] [Full Text] [Related]
4. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
5. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
6. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
7. Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.
Popov A; Henze G; Tsaur G; Budanov O; Roumiantseva J; Belevtsev M; Verzhbitskaya T; Movchan L; Lagoyko S; Zharikova L; Olshanskaya Y; Riger T; Valochnik A; Miakova N; Litvinov D; Khlebnikova O; Streneva O; Stolyarova E; Ponomareva N; Novichkova G; Aleinikova O; Fechina L; Karachunskiy A
Cancer Med; 2024 Apr; 13(8):e7172. PubMed ID: 38651186
[TBL] [Abstract] [Full Text] [Related]
8. Impact of the COVID-19 pandemic on utilization and cost for care of pediatric and young adult ALL.
Hoover A; Watson D; Reimche P; Tanner L; Gilchrist L; Finch M; Messinger YH; Turcotte LM
BMC Res Notes; 2024 Apr; 17(1):112. PubMed ID: 38644484
[TBL] [Abstract] [Full Text] [Related]
9. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Ma S; Wang Y; Qi K; Lu W; Qi Y; Cao J; Niu M; Li D; Sang W; Yan Z; Zhu F; Cheng H; Li Z; Zhao M; Xu K
Cancer Immunol Immunother; 2024 Apr; 73(6):104. PubMed ID: 38630258
[TBL] [Abstract] [Full Text] [Related]
10. Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting.
Shi T; Zhu HH
J Hematol Oncol; 2024 Apr; 17(1):18. PubMed ID: 38627786
[TBL] [Abstract] [Full Text] [Related]
11. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M; Burridge S; Kirkwood AA; Bonney D; Watts K; Shenton G; Jalowiec KA; O'Reilly MA; Roddie C; Castleton A; Clesham K; Nicholson E; Alajangi R; Prabhu S; George L; Uttenthal B; Gabelli M; Neill L; Besley C; Chaganti S; Wynn RF; Bartram J; Chiesa R; Lucchini G; Pavasovic V; Rao A; Rao K; Silva J; Samarasinghe S; Vora A; Clark P; Cummins M; Marks DI; Amrolia P; Hough R; Ghorashian S
Blood Cancer J; 2024 Apr; 14(1):66. PubMed ID: 38622139
[TBL] [Abstract] [Full Text] [Related]
12. Novel PIKfyve/Tubulin Dual-target Inhibitor as a Promising Therapeutic Strategy for B-cell Acute Lymphoblastic Leukemia.
Lu Z; Lai Q; Li ZF; Zhong MY; Jiang YL; Feng LY; Zha J; Yao JW; Li Y; Deng XM; Xu B
Curr Med Sci; 2024 Apr; 44(2):298-308. PubMed ID: 38619682
[TBL] [Abstract] [Full Text] [Related]
13. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia.
Suske T; Sorger H; Manhart G; Ruge F; Prutsch N; Zimmerman MW; Eder T; Abdallah DI; Maurer B; Wagner C; Schönefeldt S; Spirk K; Pichler A; Pemovska T; Schweicker C; Pölöske D; Hubanic E; Jungherz D; Müller TA; Aung MMK; Orlova A; Pham HTT; Zimmel K; Krausgruber T; Bock C; Müller M; Dahlhoff M; Boersma A; Rülicke T; Fleck R; de Araujo ED; Gunning PT; Aittokallio T; Mustjoki S; Sanda T; Hartmann S; Grebien F; Hoermann G; Haferlach T; Staber PB; Neubauer HA; Look AT; Herling M; Moriggl R
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618957
[TBL] [Abstract] [Full Text] [Related]
14. Shared genetic architecture between autoimmune disorders and B-cell acute lymphoblastic leukemia: insights from large-scale genome-wide cross-trait analysis.
Yu X; Chen Y; Chen J; Fan Y; Lu H; Wu D; Xu Y
BMC Med; 2024 Apr; 22(1):161. PubMed ID: 38616254
[TBL] [Abstract] [Full Text] [Related]
15. Different Levels of Therapeutic Strategies to Recover the Microbiome to Prevent/Delay Acute Lymphoblastic Leukemia (ALL) or Arrest Its Progression in Children.
Aronica TS; Carella M; Balistreri CR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612738
[TBL] [Abstract] [Full Text] [Related]
16. Metabolic Profiling as an Approach to Differentiate T-Cell Acute Lymphoblastic Leukemia Cell Lines Belonging to the Same Genetic Subgroup.
Alabed HBR; Pellegrino RM; Buratta S; Lema Fernandez AG; La Starza R; Urbanelli L; Mecucci C; Emiliani C; Gorello P
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612731
[TBL] [Abstract] [Full Text] [Related]
17. A Rare Case of Methemoglobinemia after Ifosfamide Infusion in a 3-Year-Old Patient Treated for T-ALL.
Suprunowicz M; Marcinkiewicz K; Leszczyńska E; Krętowska-Grunwald A; Płonowski M; Tałałaj M; Dakowicz Ł; Krawczuk-Rybak M; Sawicka-Żukowska M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612599
[TBL] [Abstract] [Full Text] [Related]
18. Infant Acute Lymphoblastic Leukemia-New Therapeutic Opportunities.
Kulczycka M; Derlatka K; Tasior J; Sygacz M; Lejman M; Zawitkowska J
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612531
[TBL] [Abstract] [Full Text] [Related]
19. Deep learning assists in acute leukemia detection and cell classification via flow cytometry using the acute leukemia orientation tube.
Cheng FM; Lo SC; Lin CC; Lo WJ; Chien SY; Sun TH; Hsu KC
Sci Rep; 2024 Apr; 14(1):8350. PubMed ID: 38594383
[TBL] [Abstract] [Full Text] [Related]
20. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
Huang X; Li Y; Zhang J; Yan L; Zhao H; Ding L; Bhatara S; Yang X; Yoshimura S; Yang W; Karol SE; Inaba H; Mullighan C; Litzow M; Zhu X; Zhang Y; Stock W; Jain N; Jabbour E; Kornblau SM; Konopleva M; Pui CH; Paietta E; Evans W; Yu J; Yang JJ
Cancer Cell; 2024 Apr; 42(4):552-567.e6. PubMed ID: 38593781
[TBL] [Abstract] [Full Text] [Related]
[Next]
